Prostate cancer is typically diagnosed in men ≥65 years of age, many of whom have one or more comorbidities, often including cardiovascular comorbidities, thus highlighting a need to understand the risks of cardiovascular toxicities associated with prostate cancer treatments. In this Review, the authors describe the evidence linking widely used treatments of prostate cancer, including androgen deprivation therapies, chemotherapies and targeted therapies with cardiovascular adverse events.
- Antonello Veccia
- Francesca Maines
- Orazio Caffo
